Loomis, Sayles & Company
KYNB icon

Loomis, Sayles & Company’s Kyntra Bio KYNB Stock Holding History

Loomis, Sayles & Company’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4
Closed -$2K – 1049
2016
Q3 		$2K Hold
4
– – ﹤0.01% 960
2016
Q2 		$1K Hold
4
– – ﹤0.01% 970
2016
Q1 		$2K Buy
+4
New +$1.99K ﹤0.01% 992

Other funds holding KYNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Loomis, Sayles & Company's KYNB Position: Q4 2016 in Review

Loomis, Sayles & Company sold out of Kyntra Bio (KYNB) in Q4 2016, closing a stake of 4 shares — an estimated $2K sold.

Loomis, Sayles & Company first reported a position in KYNB in Q1 2016 and held it in 3 quarters. The position peaked at $2K in Q3 2016. 140 funds tracked by Wall St. Rank hold KYNB as of Q4 2016.

  • Loomis, Sayles & Company reported no remaining Kyntra Bio position as of Q4 2016 after selling out during the quarter.
  • Loomis, Sayles & Company sold 4 Kyntra Bio shares in Q4 2016, an estimated $2K.
  • Loomis, Sayles & Company first reported a position in Kyntra Bio in Q1 2016 and held it in 3 quarters.
  • Loomis, Sayles & Company's Kyntra Bio position peaked at $2K in Q3 2016.
  • 140 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2016.

Based on Loomis, Sayles & Company's 13F filing for Q4 2016, filed 14 Feb 2017.